The Safety of Anticoagulation Therapy in Liver Cirrhosis Portal Vein Thrombosis and Its Impact on Hospital Outcomes.

The Safety of Anticoagulation Therapy in Liver Cirrhosis Portal Vein Thrombosis and Its Impact on Hospital Outcomes.

2024.01.11
"The Hepatology Digest -Liver Vascular Disease Column" is an academic section jointly initiated by Dr. Xingshun Qi of the Department of Gastroenterology, Northern Theater General Hospital, at the invitation of the Hepatology Digest editorial team. It regularly collects and discusses the latest research in the field of liver vascular diseases. Every two weeks, on Wednesdays, it features an in-depth discussion of a significant publication, aiming to enlighten readers about the rationale behind these findings and inspire clinical research and practical application.

The Treatment and Clinical Cure of Childhood Hepatitis B

2024.01.10
China is a country with a high incidence of hepatitis B, and mother-to-child transmission is an important route for children in China to contract the hepatitis B virus (HBV). Although chronic HBV infection in childhood rarely progresses to active hepatitis, there is still a risk of developing cirrhosis and liver cancer. Therefore, understanding the epidemiological characteristics of childhood hepatitis B and taking effective prevention and control measures are particularly important to reduce the incidence of childhood hepatitis B in China and promote healthy growth. In recent years, as the goal of clinical cure for hepatitis B has gradually gained more attention, the issue of clinical cure for childhood hepatitis B has also received increasing focus. At the recently concluded "15th Academic Conference on Antiviral Therapy Difficulties and Hotspots in Chronic Viral Hepatitis," Dr. Fusheng Wang from the Fifth Medical Center of the PLA General Hospital presented a special report on "Treatment and Clinical Cure of Childhood Hepatitis B," offering an in-depth analysis of these issues.

CDL (co-management of diabetes-liver diseases strategy,) Literature Monthly Review – November 2023, Issue 10

2024.01.10
Diabetes and liver diseases are common chronic conditions in China, and they interact in terms of pathogenesis, clinical manifestations, and therapeutic targets, often posing mutual risk factors. Co-management of these conditions is beneficial for reducing the burden of disease. To support the development of diabetes and liver disease co-management in China, this publication Hepatology Digest, in collaboration with the co-management of diabetes-liver diseases strategy, (CDL), presents the CDL Literature Monthly Review column. Each month, we share research literature related to the mechanisms and therapeutic advances in diabetes combined with liver diseases. We invite experts in the field to comment on the literature, hoping to provide insights and assistance for professionals, researchers, and frontline medical workers engaged in scientific research and clinical diagnosis and treatment.
CDM Monthly Review (November 2023, Issue 75)

CDM Monthly Review (November 2023, Issue 75)

2024.01.10
Hello experts and colleagues, in this 75th issue of the CDM Monthly Review for November 2023, we share six recent publications in the field of portal hypertension diagnosis and treatment (three on diagnosis and monitoring, and three on multidisciplinary treatment). This issue features guest experts: Dr. Bingtian Dong from the Department of Ultrasound at the First Affiliated Hospital of Anhui Medical University, Dr.Ningning Wang from the Department of Gastroenterology at the First Affiliated Hospital of China Medical University, Dr.Lei Zheng from the Department of General Surgery at the Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine, and Dr. Sheng Wang from the Department of Gastroenterology at the Third Affiliated Hospital of Sun Yat-sen University.

Application of Ultrasound Elastography Scoring in Diagnosing Potential Porto-Sinusoidal Vascular Disease in Patients with Portal Vein Thrombosis

2024.01.09
The "Hepatology Digest-Vascular Liver Disease Column" is an academic column jointly initiated by Dr. Xingshun Qi of the Department of Gastroenterology, Northern Theater Command General Hospital, at the invitation of the editorial department of " Hepatology Digest". This column regularly collects and organizes research progress in the field of vascular liver disease. Every two weeks (on Wednesday), an important piece of literature is selected for in-depth discussion. The aim is to help readers understand the rationale behind these advancements and to inspire clinical and scientific thinking, putting knowledge into practice.
From “Clinical Cure” to “Disease Cure” – The Long-term Treatment of Chronic Hepatitis B

From “Clinical Cure” to “Disease Cure” – The Long-term Treatment of Chronic Hepatitis B

2024.01.09
From November 17-19, 2023, the "15th Chronic Viral Hepatitis Antiviral Treatment Difficulties and Hotspots Academic Conference" was grandly held in Chongqing. Sponsored by the Chinese Medical Journal Co., Ltd., organized by the Editorial Department of the Chinese Journal of Hepatology, and co-organized by the Hepatitis Group of the Chinese Society of Hepatology of the Chinese Medical Association (CMA), the Second Affiliated Hospital of Chongqing Medical University, and the Viral Hepatitis Research Institute of Chongqing Medical University, the conference focused on chronic viral hepatitis treatment and high-quality development of the discipline, providing a platform for information exchange and interaction among frontline clinicians and clinical researchers. Dr. Xiaoguang Dou from Shengjing Hospital of China Medical University, the chairman of the conference, shared the highlights and engaged in an in-depth interview on the hot topic of chronic hepatitis B clinical treatment. The content is organized for the readers' benefit.
Construction and Validation of a Hepatocellular Carcinoma Prognosis Model Based on Stress Granules

Construction and Validation of a Hepatocellular Carcinoma Prognosis Model Based on Stress Granules

2024.01.08
In an effort to keep clinicians and researchers in the field of hepatology abreast of the latest academic knowledge and research trends, " Hepatology Digest " has collaborated with the "Journal of Clinical and Translational Hepatology" (JCTH) to introduce the "Journal Co-Read" section. Each week, this section selects and interprets highlights from a key publication, summarizing its main points in the hope of enhancing clinical diagnostic and treatment levels, inspiring research thinking, and improving writing skills.

Efficacy Analysis of “T+A” Therapy in Different Treatment Populations of HCC

2024.01.08
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Most patients are unable to undergo surgical resection at the time of diagnosis, making systemic therapy an important treatment approach for this group. The combination immunotherapy of Atezolizumab plus Bevacizumab (“T+A”) has become the new first-line standard treatment for unresectable HCC patients due to its significant improvement in overall survival (OS) compared to sorafenib. However, its effectiveness in different populations, including HCC patients with different etiologies, Child-Pugh B grade HCC, and intermediate-stage HCC beyond the up-to-seven criteria, remains unclear. The journal "Hepatology Digest" has reviewed recent studies on this topic for the benefit of readers.
Progress and considerations in the research of malnutrition in patients with cirrhosis

Progress and considerations in the research of malnutrition in patients with cirrhosis

2024.01.08
Malnutrition, a subacute or chronic nutritional condition, arises from insufficient (or excessive) food intake and/or inflammation, leading to compromised body composition and reduced bodily functions, adversely affecting clinical outcomes and prognosis. Given the liver's central role in metabolizing glucose, proteins, and fats, patients with ongoing liver damage, especially cirrhosis, commonly suffer from malnutrition. Studies indicate that 40% to 90% of hospitalized patients with liver disease experience malnutrition. It is an independent predictor of mortality in cirrhosis patients and is closely linked to complications like ascites, hepatic encephalopathy, infections, and recent findings also suggest connections with reduced quality of life, sleep disorders, micronutrient deficiencies, and frailty.
The clinical insights gained from T-cell receptor sequencing in revealing the immune characteristics of liver cancer staging

The clinical insights gained from T-cell receptor sequencing in revealing the immune characteristics of liver cancer staging

2024.01.08
T lymphocytes play a crucial role in human adaptive immunity by recognizing antigens major histocompatibility complex (MHC) molecules through specific T-cell receptors (TCRs) on their surface. 95% of T cells have TCRs composed of α and β peptide chains connected by disulfide bonds, forming an α/β heterodimer. Each chain consists of constant and variable domains. TCR diversity arises from the rearrangement of the variable (V), diversity (D), and joining (J) gene segments of the peptide chains, along with random nucleotide additions or deletions.